142 related articles for article (PubMed ID: 32215689)
1. Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap).
Schuster-Little N; Madera S; Whelan R
Anal Bioanal Chem; 2020 Sep; 412(24):6361-6370. PubMed ID: 32215689
[TBL] [Abstract][Full Text] [Related]
2. Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites.
Schuster-Little N; Fritz-Klaus R; Etzel M; Patankar N; Javeri S; Patankar MS; Whelan RJ
Analyst; 2021 Jan; 146(1):85-94. PubMed ID: 33141132
[TBL] [Abstract][Full Text] [Related]
3. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R
Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117
[TBL] [Abstract][Full Text] [Related]
4. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
[TBL] [Abstract][Full Text] [Related]
5. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
6. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
7. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
[TBL] [Abstract][Full Text] [Related]
8. Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry.
Weiland F; Fritz K; Oehler MK; Hoffmann P
Int J Mol Sci; 2012; 13(8):9942-9958. PubMed ID: 22949840
[TBL] [Abstract][Full Text] [Related]
9. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract][Full Text] [Related]
10. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
Bayoumy S; Hyytiä H; Leivo J; Talha SM; Huhtinen K; Poutanen M; Hynninen J; Perheentupa A; Lamminmäki U; Gidwani K; Pettersson K
Commun Biol; 2020 Aug; 3(1):460. PubMed ID: 32826955
[TBL] [Abstract][Full Text] [Related]
11. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
12. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
13. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
14. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
[TBL] [Abstract][Full Text] [Related]
15. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
17. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma.
Saygili U; Guclu S; Uslu T; Erten O; Dogan E
Int J Gynecol Cancer; 2002; 12(5):438-42. PubMed ID: 12366659
[TBL] [Abstract][Full Text] [Related]
18. Gold nanoparticle enhanced hybridization chain reaction as a method for signal amplification. Application to electrochemical immunodetection of the ovarian cancer biomarker carbohydrate antigen 125.
Nie Y; Yang M; Ding Y
Mikrochim Acta; 2018 Jun; 185(7):331. PubMed ID: 29915871
[TBL] [Abstract][Full Text] [Related]
19. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
[TBL] [Abstract][Full Text] [Related]
20. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
